Alnylam Pharmaceuticals (ALNY) is trading down at $143.82 (-2.71%) on NASDAQ, as of the latest quote. It is a Nasdaq-100 constituent in the Health Care sector.
What the tracked firms say
9 open price targets on Alnylam Pharmaceuticals from 8 firms, as of Nov 2, 2026 (the newest target counted).
3 firms stated no rating.
Counted from the targets listed below: each firm once, at its latest open target. Ratings are the firms' own words, grouped only where the word is unambiguous. This is a summary of what the firms published, not a forecast or advice from Dalsna Finance, and it is not a consensus estimate. How we collect and score targets.
9 targets, newest first. Open a row for its source and scoring.
Entry price $161, the close nearest Nov 2, 2026, when the target was reported; the target is +40% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.
Scoring Open: judged on the close on Nov 2, 2027.
ALNY Downgraded by Truist Securities -- Price Target Lowered to $225
Entry price $158, the close nearest Nov 2, 2026, when the target was reported; the target is +104% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.
Scoring Open: judged on the close on Nov 2, 2027.
ALNY Maintained by Canaccord Genuity -- Price Target Lowered to $323
Entry price $165, the close nearest Oct 30, 2026, when the target was reported; the target is +21% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.
Scoring Open: judged on the close on Oct 30, 2027.
ALNY Downgraded by Bernstein -- Price Target Lowered to $199
Entry price $174, the close nearest Oct 30, 2026, when the target was reported; the target is +101% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.
Scoring Open: judged on the close on Oct 30, 2027.
Freedom Broker lowered its price target on Alnylam Pharmaceuticals (NASDAQ:ALNY) to $350 from $410
Entry price $165, the close nearest Oct 30, 2026, when the target was reported; the target is +70% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.
Scoring Open: judged on the close on Oct 30, 2027.
ALNY Maintained by RBC Capital -- Price Target Lowered to $280
Entry price $165, the close nearest Oct 30, 2026, when the target was reported; the target is +91% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.
Scoring Open: judged on the close on Oct 30, 2027.
ALNY Downgraded by Raymond James -- Price Target Lowered to $315
Entry price $174, the close nearest Oct 29, 2026, when the target was reported; the target is +40% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.
Scoring Open: judged on the close on Oct 29, 2027.
Needham cut its target price for Alnylam Pharmaceuticals to $243 from $357.
Entry price $174, the close nearest Oct 29, 2026, when the target was reported; the target is +29% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.
Scoring Open: judged on the close on Oct 29, 2027.
Stifel downgraded Alnylam (ALNY) to Hold from Buy with a price target of $225, down from $318
Entry price $224, the close nearest Oct 23, 2026, when the target was reported; the target is +87% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.
Scoring Open: judged on the close on Oct 23, 2027.
Raymond James reiterated a Strong Buy rating and $420.00 price target on Alnylam Pharmaceuticals
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
8 firms have a price target on Alnylam Pharmaceuticals tracked here, newest first. Each links to that firm's full record.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $47.2M | $89.9M | $74.9M | $219.8M | $492.9M | $844.3M | $1.04B | $1.83B | $2.25B | $3.71B |
| Growth (year over year) | — | +90.7% | −16.7% | +193.4% | +124.3% | +71.3% | +22.9% | +76.2% | +23.0% | +65.2% |
| Gross profit | — | $89.9M | $73.1M | $194.7M | $418.7M | $729.3M | $897.2M | $1.56B | $1.94B | $3.04B |
| Gross margin | — | 100.0% | 97.6% | 88.6% | 84.9% | 86.4% | 86.5% | 85.3% | 86.4% | 81.8% |
| Operating income | −$424.6M | −$500.1M | −$814.7M | −$939.4M | −$828.4M | −$708.7M | −$785.1M | −$282.2M | −$176.9M | $501.6M |
| Operating margin | −900.3% | −556.2% | −1087.6% | −427.5% | −168.1% | −83.9% | −75.7% | −15.4% | −7.9% | 13.5% |
| Net income | −$410.1M | −$490.9M | −$761.5M | −$886.1M | −$858.3M | −$852.8M | −$1.13B | −$440.2M | −$278.2M | $313.7M |
| Net margin | −869.6% | −545.9% | −1016.6% | −403.2% | −174.1% | −101.0% | −109.0% | −24.1% | −12.4% | 8.4% |
| EPS (diluted) | −$4.79 | −$5.42 | −$7.57 | −$8.11 | −$7.46 | −$7.20 | −$9.30 | −$3.52 | −$2.18 | $2.33 |
| Balance sheet | ||||||||||
| Cash and equivalents | $193.6M | $645.4M | $420.1M | $547.2M | $496.6M | $820.0M | $866.4M | $812.7M | $966.4M | $1.66B |
| Total assets | $1.26B | $1.99B | $1.57B | $2.40B | $3.41B | $3.64B | $3.55B | $3.83B | $4.24B | $4.97B |
| Total liabilities | $342.6M | $228.3M | $272.8M | $956.4M | $2.39B | $3.06B | $3.70B | $4.05B | $4.17B | $4.18B |
| Long-term debt | — | — | — | — | $191.3M | $675.7M | — | — | — | — |
| Shareholders' equity | $920.2M | $1.77B | $1.30B | $1.44B | $1.02B | $588.2M | −$158.2M | −$220.6M | $67.1M | $789.2M |
| Cash flow | ||||||||||
| Operating cash flow | −$307.7M | −$382.8M | −$562.6M | −$278.4M | −$615.0M | −$641.7M | −$541.3M | $104.2M | −$8.31M | $524.1M |
| Capital expenditure | $64.6M | $104.2M | $126.9M | $140.2M | $70.4M | $76.4M | $72.1M | $62.2M | $34.3M | $58.7M |
| Free cash flow | −$372.3M | −$487.0M | −$689.5M | −$418.6M | −$685.3M | −$718.1M | −$613.3M | $41.9M | −$42.6M | $465.4M |
| Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26†Mar 2026 | Q2 FY26Jun 2026 | Q3 FY26Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $593.2M | $594.2M | $773.7M | $1.25B | $1.10B | $1.17B | $1.29B | $1.46B |
| Growth (year over year) | +34.9% | +20.2% | +17.3% | +149.3% | +84.9% | +96.4% | +66.9% | +16.7% |
| Gross profit | $490.5M | $524.0M | $631.7M | $1.05B | $829.3M | $959.7M | $992.7M | $1.10B |
| Gross margin | 82.7% | 88.2% | 81.6% | 84.2% | 75.6% | 82.2% | 76.9% | 75.2% |
| Operating income | −$105.2M | $18.1M | −$16.2M | $368.0M | $131.7M | $268.6M | $231.4M | $345.8M |
| Operating margin | −17.7% | 3.0% | −2.1% | 29.5% | 12.0% | 23.0% | 17.9% | 23.7% |
| Net income | −$83.8M | −$18.3M | −$72.2M | $292.7M | $111.5M | $206.0M | $164.5M | $2.17B |
| Net margin | −14.1% | −3.1% | −9.3% | 23.4% | 10.2% | 17.6% | 12.7% | 148.6% |
| EPS (diluted) | −$0.65 | −$0.14 | −$0.55 | $2.14 | $0.82 | $1.50 | $1.21 | $15.72 |
| Balance sheet | ||||||||
| Cash and equivalents | $966.4M | $1.02B | $1.11B | $1.49B | $1.66B | — | $1.71B | $1.75B |
| Total assets | $4.24B | $4.21B | $4.57B | $4.85B | $4.97B | — | $5.56B | $7.99B |
| Total liabilities | $4.17B | $4.10B | $4.32B | $4.62B | $4.18B | — | $4.20B | $4.39B |
| Shareholders' equity | $67.1M | $426.1M | $555.3M | $580.2M | $789.2M | $1.08B | $1.35B | $3.60B |
| Cash flow | ||||||||
| Operating cash flow | −$94.7M | −$118.3M | $127.8M | $296.9M | $217.7M | — | — | $341.0M |
| Capital expenditure | $9.09M | $8.97M | $14.3M | $12.1M | $23.3M | — | — | $69.8M |
| Free cash flow | −$103.8M | −$127.3M | $113.5M | $284.7M | $194.4M | — | — | $271.2M |
From Alnylam Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
The last 8 quarters as Alnylam Pharmaceuticals (ALNY) reported them to the SEC: revenue and diluted earnings per share under GAAP, as filed (a figure marked * is our calculation, not a filed one). No estimates. The change columns are our calculation from these figures.
| Fiscal quarter | Reported | Revenue | vs prior quarter (our calculation) | vs a year earlier (our calculation) | Diluted EPS | vs prior quarter (our calculation) | vs a year earlier (our calculation) | Filings |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026Jul–Sep 2026 | Oct 29, 2026 | $1.46B | +12.9% | +16.7% | $15.72 | +1199.2% | +634.6% | 8-K results · 10-Q |
| Q2 FY2026Apr–Jun 2026 | Jul 30, 2026 | $1.29B | +10.6% | +66.9% | $1.21 | n/a | n/a | 8-K results · 10-Q |
| Q1 FY2026Jan–Mar 2026 | Apr 30, 2026 | $1.17B* | +6.4% | +96.4% | —† | n/a | n/a | 8-K results |
| Q4 FY2025Oct–Dec 2025 | Feb 12, 2026 | $1.10B* | −12.2% | +84.9% | —† | n/a | n/a | 8-K results · 10-K |
| Q3 FY2025Jul–Sep 2025 | Oct 30, 2025 | $1.25B | +61.4% | +149.3% | $2.14 | n/a | n/a | 8-K results · 10-Q |
| Q2 FY2025Apr–Jun 2025 | Jul 31, 2025 | $773.7M | +30.2% | +17.3% | −$0.55 | n/a | n/a | 8-K results · 10-Q |
| Q1 FY2025Jan–Mar 2025 | May 1, 2025 (10-Q filed) | $594.2M | +0.2% | +20.2% | −$0.14 | n/a | n/a | 10-Q |
| Q4 FY2024Oct–Dec 2024 | Jan 13, 2025 | $593.2M* | +18.4% | +34.9% | —† | n/a | n/a | 8-K results · 10-K |
"Reported" is the day the results release (an 8-K under Item 2.02) was accepted by the SEC; where we have none on file it is the day the quarterly or annual report was filed, and says which. * Our calculation: revenue for a fourth quarter the company reports only within its full year, worked out as the 10-K's year less the first three quarters. † Not shown: the company reports this quarter's diluted EPS only within its full year, and per-share amounts do not add up across quarters (the share count changes), so the year less nine months would differ from the company's own fourth-quarter figure. Changes against it are left blank too. n/a: no comparable quarter, or a zero or negative base, where a percentage would mislead. Source: the company's filings on SEC EDGAR.
Read at Stock Titan ↗ Link to this story
Also mentions Regeneron Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Source: Wikipedia — Alnylam Pharmaceuticals
No public reader scorecards on Alnylam Pharmaceuticals yet. Set a price target with a date and it is scored in public.
Make your own scorecardHow federal capital gains are taxed (general information, not tax advice)